The present disclosure relates to a strain of Lactobacillus sakei HEM224 (KCTC14065BP) and a composition for treating, preventing or alleviating inflammation or asthma, comprising the strain.

A strain of Lactobacillus sakei HEM224 (KCTC14065BP) according to an embodiment of the present disclosure inhibits the production of pro-inflammatory factors or inflammatory factors, and exhibits an effect of treating asthma in an asthma animal model. Therefore, the strain can be applied to pharmaceutical compositions, food compositions, health functional food compositions and feed compositions for treating, preventing or alleviating inflammation or asthma.

The present disclosure relates to a composite composition of 2-methoxyestradiol and Chir99021 for the treatment of fibrosis. The composition according to the present disclosure inhibits collagen deposition and inflammatory response, and prevents the fibrosis of blood vessels and tissue damage, and thus has excellent preventive and therapeutic effects on fibrosis.

The present invention relates to a pharmaceutical composition for preventing or treating COVID-19 diseases, comprising an organic solvent extract of Justicia procumbens as an effective ingredient, a pharmaceutical composition for preventing or treating COVID-19 diseases, comprising justicidin-A as an effective ingredient, a pharmaceutical composition for preventing or treating COVID-19 diseases, comprising justicidin-B as an effective ingredient, or a pharmaceutical composition for preventing or treating COVID-19 diseases, comprising 6′ hydroxyl justicidin-B as an effective ingredient, and a food composition thereof for preventing or ameliorating COVID-19 diseases. According to the present invention, an anhydrous ethanol extract of Justicia procumbens, justicidin-A, justicidin-B, and 6′ hydroxyl justicidin-B effectively inhibit SARS-CoV-2 virus, and thus may effectively prevent, treat, or ameliorate diseases caused by SARS-CoV-2 virus.

The present invention relates to a pharmaceutical composition for preventing or treating COVID-19 diseases, comprising an organic solvent extract of Justicia procumbens as an effective ingredient, a pharmaceutical composition for preventing or treating COVID-19 diseases, comprising justicidin-A as an effective ingredient, a pharmaceutical composition for preventing or treating COVID-19 diseases, comprising justicidin-B as an effective ingredient, or a pharmaceutical composition for preventing or treating COVID-19 diseases, comprising 6′ hydroxyl justicidin-B as an effective ingredient, and a food composition thereof for preventing or ameliorating COVID-19 diseases. According to the present invention, an anhydrous ethanol extract of Justicia procumbens, justicidin-A, justicidin-B, and 6′ hydroxyl justicidin-B effectively inhibit SARS-CoV-2 virus, and thus may effectively prevent, treat, or ameliorate diseases caused by SARS-CoV-2 virus.

The present disclosure relates to a composition of a complex comprising metformin and Chir99021 for treating fibrosis. The composition according to the present disclosure inhibits collagen deposition and inflammatory responses and prevents vascular fibrosis and tissue damage, thereby exhibiting excellent prevention and therapeutic effects against fibrosis.

Novel strains of Lactobacillus plantarum GCWB1001 deposited as accession number KCCM12698P, Pediococcus acidilactici GCWB1085 deposited as accession number KCCM12699P, or Lactobacillus rhamnosus GCWB1156 deposited as accession number KCCM12700P are disclosed. The novel strains have the excellent effect of treating or alleviating respiratory diseases. Additionally, provided are a pharmaceutical composition, a health functional food composition, and probiotics, all of which have the effect of treating or alleviating inflammatory diseases or respiratory diseases, containing any one of the novel strains.

Novel strains of Lactobacillus plantarum GCWB1001 deposited as accession number KCCM12698P, Pediococcus acidilactici GCWB1085 deposited as accession number KCCM12699P, or Lactobacillus rhamnosus GCWB1156 deposited as accession number KCCM12700P are disclosed. The novel strains have the excellent effect of treating or alleviating respiratory diseases. Additionally, provided are a pharmaceutical composition, a health functional food composition, and probiotics, all of which have the effect of treating or alleviating inflammatory diseases or respiratory diseases, containing any one of the novel strains.

The disclosure features a human milk cream composition, standardized high fat human milk formulations as well as methods of making and using such compositions. In particular, the disclosure features a method of using a human milk cream composition and/or standardized high fat human milk formulations to treat infants with bronchopulmonary dysplasia (BPD) or at risk of developing BPD.

The disclosure features a human milk cream composition, standardized high fat human milk formulations as well as methods of making and using such compositions. In particular, the disclosure features a method of using a human milk cream composition and/or standardized high fat human milk formulations to treat infants with bronchopulmonary dysplasia (BPD) or at risk of developing BPD.

The present disclosure relates to a method of altering intestinal microbiome in a patient having cystic fibrosis comprising administering at least one of Bifidobacterium and/or Bacteroides to a patient and allowing the Bifidobacterium and/or Bacteroides to alter the intestinal microbiome.